qPharmetra’s team draws on broad experiences across therapeutic areas and stages of drug development to use the right analysis for your challenges.
We are currently 26 scientists located in the US and Europe. We value diversity and educational backgrounds include Pharmacometrics, Systems Pharmacology, Pharmaceutical Sciences, Engineering, and Biomathematics. All consultants hold at least a Master’s Degree, and >75% hold a PhD as their terminal degree. We are a team that works closely together to share our knowledge to help our clients make better decisions
Alexander Völkner, PhD
Senior Consultant
Alix Démaris, PharmD
Associate Consultant
Alix joined qPharmetra team in April 2023 as an Associate Consultant. She got her Pharmacy degree from Université Paris Descartes, where she gained experience in the use of pharmacometrics in therapeutic drug monitoring at Hôpital Beaujon and Inserm UMR1137, and drug development at Sanofi.
After graduating, she started her PhD at Freie Universität Berlin , where her research focused on optimizing infliximab therapy in patients with inflammatory bowel diseases. She applied mixed hidden Markov and population pharmacokinetic (popPK) models to investigate the development of immunogenicity in Crohn’s disease patients receiving infliximab therapy and the impact of disease severity on infliximab clearance in acute severe ulcerative colitis patients.
Since joining qPharmetra, Alix has expanded her expertise in PK/PD modeling, especially in oncology developing various PD models for safety and efficacy.
Anja Henningsson, PhD
CEO
As of October 2020, Anja Henningsson is qPharmetra’s CEO but has been Acting-CEO since February 2020. She has been part of the management team since July 2018 while helping clients with expertise in pharmacometrics, clinical pharmacology and regulatory submissions. Anja is highly engaged in people development and the qPharmetra way of working. She actively participates in our expert teams and collaborates with the client to identify key questions and fit for purpose solutions to support the client’s decision-making process.
Anja started her journey in pharmacometrics with a PhD from Uppsala University in 2005. She further developed her capabilities in model-based drug development and clinical pharmacology as a pharmacometrics reviewer at the Swedish MPA, and as an industry pharmacometrician and has been a consultant with qPharmetra since 2014.
Anne Brochot, MSc, MBA
Senior Consultant
Anne joined qPharmetra in August 2024 with more than 20 years of experience in the pharmaceutical industry, supporting projects throughout the drug development process from drug discovery to post-marketing. She worked in both small and large-sized pharmaceutical companies, including biotech, and focused on implementing and conducting model-informed drug development strategies and analyses.
Anne has extensive experience across various therapeutic areas, with specialized expertise in infectious diseases and the central nervous system. She has also developed significant expertise in pediatric drug development, including drugs for pediatric-only applications.
Anne holds a Chemical Engineer degree (MSc) from the Ecole Nationale Supérieure de Chime de Montpellier in France, and an MBA degree from the Vlerick Business School in Belgium.
Ben Suttle, PhD
Principal Consultant
Ben joined qPharmetra in March 2018 with 25 years of experience in the pharmaceutical industry supporting projects throughout the drug development process from clinical candidate selection through approval and post-marketing studies. He has worked in both large and small pharmaceutical companies as well as in biotech to design and implement the clinical pharmacology strategy to support the successful global registration of medications. Ben has extensive experience in the development of medications to treat cancer but also has experience in other therapeutic areas including diseases of the lung, central nervous system disorders, infectious diseases, dermatology, and gastrointestinal disorders. Ben brings extensive experience in interactions with the FDA, including Oncologic Drug Advisory Committee meetings, Health Canada, and European regulatory agencies.
Elisa Hodge, BSc
Financial Analyst
Elisa has been an integral member of the Finance team since the early years of qPharmetra. In her role, she creates invoices, researches and arranges face-to-face meeting venues, and provides analytical and administrative support. Before joining qPharmetra, Elisa dedicated time to raising her children and engaging in volunteer work. Previously, she worked on developing computer-based training (CBT) programs and documentation for proprietary software systems. Elisa is committed to assisting clients with their invoicing needs and collaborates closely with consultants to ensure adherence to budgets.
Eva Hanze, MSc
Principal Consultant
Eva joined qPharmetra in 2014, bringing her expertise in population pharmacokinetics (PK), pharmacokinetics-pharmacodynamics (PKPD), and exposure-response analyses to drive informed decision-making. In her current role, she leads a range of modeling projects, developing strategic plans, and executing population PK and PKPD analyses to ensure compliance with regulatory standards. Her contributions have been significant in multiple successful NDA submissions across various therapeutic areas.
In addition to her technical responsibilities, Eva actively participates in business development, representing qPharmetra in client meetings and overseeing Statements of Work.
Prior to joining qPharmetra, Eva accumulated eight years of experience at AstraZeneca, where she applied her pharmacokinetic and modeling expertise to numerous projects, particularly in neuroscience. She holds an MSc in Chemical Engineering from Uppsala University, with a focus on pharmaceutical sciences and pharmacometric modeling.
Farrah Sadre-Marandi, PhD
Senior Consultant, Business Development Manager
Farrah joined qPharmetra in August 2018 and specializes in PKPD analyses, including mechanistic models, exposure-response, and exposure-safety relationships to support dose selection, pediatric study designs, and regulatory submissions.
Farrah has a diverse academic and research background, focusing on mathematical biology, applied dynamical systems, and biostatistics. She earned her PhD in Mathematics from Colorado State University in 2015 and later completed a postdoctoral fellowship in mathematical biology at the Mathematical Biosciences Institute. Her research spanned several areas, including viral capsid structures, HIV-1 nucleic acid-protein interactions, and biochemical models addressing public health topics such as arsenic detoxification, depression, and gender differences in metabolism. Farrah’s expertise in applied mathematics and biostatistics has contributed to personalized medicine and nutritional science, using innovative mathematical techniques to address complex biological and physiological systems.
Outside of work Farrah enjoys hiking in the Colorado mountains, playing the piano, and exploring her passion for photography.
Fredrik Jonsson, PhD
Principal Consultant
Fredrik joined qPharmetra in July 2016 and brought 10 years’ experience in pharmacometric consulting to the team, primarily gained through his positions at Pharsight/Certara. He has worked in a large number of therapeutic areas, including cardiovascular, neuroscientific, oncology, virology and renal disease. He obtained his PhD in toxicokinetics at the National Institute for Working Life in Stockholm, Sweden, applying Bayesian estimation techniques to PBPK models for risk assessment purposes. He followed his dissertation with three years of post-doctoral research at the Uppsala University Pharmacometrics Group, with a focus on modeling of ordered categorical data.
During his years working for qPharmetra, he has extended his skills in sales and business development, and is, to an increasing degree, supervising more junior consultants.
Ingrid Haglund, MSc
Compliance Manager
Ingrid Haglund joined qPharmetra in September 2023 as Compliance Manager.
She works with different kinds of compliance, from privacy and GDPR issues to IT and the qPharmetra way of working through ensuring standard operating procedures, overseeing qPharmetra’s quality management system etc.
Ingrid has a decade long background as a public affairs consultant and compliance officer in one of Europe’s largest consulting firms, as well as experience from the Swedish Government Ministry for Foreign Affairs and Prime Minister’s office focused on international relations and EU Affairs. During her years in consulting Ingrid worked primarily with pharmaceutical and MedTech companies, and their interactions with decision makers on local, regional, national and EU level. She has developed trainings and outreach programs for internal use as well as for clients.
Ingrid holds a Master of Political science from Lund University and has also studied EU International Relations and Diplomacy at the College of Europe in Bruges, Belgium.
Jan Huisman, BEng
Senior Data Scientist, Team Lead Data Management
Before joining qPharmetra in 2014, Jan worked for more than 25 years as a Senior Scientist in the pharmaceutical industry with the main focus on data management and non-compartmental analyses using SAS. In that role he contributed to numerous projects spanning the entire clinical development process, from Phase 1 to Phase 3, in the Women’s Health (contraception, infertility, and HRT) and CNS (depression and anesthesiology) areas.
At qP, his activities focus on planning and executing dataset preparation, non-compartmental PK analysis, and quality control. He wrote several SOPs and manuals regarding PK analyses and data-management and he familiarized himself with the R language. Using that newly obtained knowledge he developed an R package for streamlined and standardized non-compartmental analysis.
Jan holds a Bachelor of Engineering in Analytical Chemistry.
Jantine Brussee, PhD
Consultant
Jantine joined qPharmetra in April 2023, specializing in population PK and PKPD analyses to support regulatory submissions for drug approval. In her role, she provides pharmacometric modeling to support dose selection and optimize study designs, contributing to accelerated drug development. Before joining qPharmetra, Jantine worked as a Modeling and Simulation Scientist at Idorsia Pharmaceuticals, supporting drug development across various therapeutic areas.
She holds a PhD in Pharmacology from Leiden University, where her research focused on pharmacometrics to characterize CYP3A-mediated first-pass and systemic metabolism in neonates, infants, and children. In addition to her research, she contributed to academic governance and was actively involved in teaching activities in pharmacology at Leiden University. After, she worked as a post-doctoral scientist at the Swiss Tropical and Public Health Institute and the University’s Children Hospital in Basel, applying modeling techniques to optimize pediatric dosing. Outside of work, Jantine enjoys gardening, traveling across Europe, and is rarely without her e-reader, always ready for her next great read.
Julia Fullenkamp, MSc
Data Scientist
Julia joined qPharmetra in September 2023 as a Junior Data Scientist working from her home office in Celle, Germany, and was promoted to Data Scientist in November 2024. Her primary contributions include dataset preparation and quality control. She received her BSc in Statistics and Analytics from the University of North Carolina at Chapel Hill and her MSc in Quantitative Data Science from the University of Tübingen in 2023. There, her training included a strong theoretical background in statistical analysis methods and machine learning with a focus on multidisciplinary applications. During her studies, Julia worked at the Fraunhofer Institute of Optronics, System Technologies, and Image Exploitation on the Data Modeling and Analysis for Digital Health project. There, she applied network-based machine learning techniques to assist in the development of a clinical decision support model for oncological therapeutic processes.
Karl Gustav Jostell, PhD
Principal Consultant
K-G joined qPharmetra in January 2018 and has 35+years experience in the areas of pre-clinical DMPK and Clinical Pharmacology from Astra/AstraZeneca. K-G has mainly worked in the CNS area and he has special interest in design and interpretation of Clinical Pharmacology studies and development programs in the field. K-G has a PhD and holds a MSc in Pharmaceutical Science, both at Uppsala University, and is a Pharmacist by training.
Klaas Prins, PhD
Chairman of the Board, Head of Business Development
Klaas is a co-founder of qPharmetra and is currently Chairman of the Board. He leads the company’s business development transforming clients’ available data and key questions into creative and decisive projects. He also continues to create models and consult with clients. He combines rigorous focus on the technical details of integrated pharmacometric analysis with pragmatism and clear communication.
Prior to qPharmetra, Klaas gained drug development experience as a clinical pharmacokineticist involved in the design and analysis of clinical studies in the fields of neurology, fertility and gastroenterology. His PhD thesis focused on the application of classical, analytical, pharmacological principles to advance the development of drugs promoting motility in impaired gastrointestinal systems. He holds an MSc in pharmacy and obtained his PhD in experimental medicine at Utrecht University. When he is not working, Klaas loves to play jazz and funk on the Fender Rhodes piano, constantly seeking a balance between musical math and the freedom of playing from the heart.
Klas Petersson, PhD
Principal Consultant
Klas joined qPharmetra in October of 2012 and has over the years built up a substantial experience in pharmaceutical development. Specifically, how to leverage the use of modeling and simulation efficiently and robustly for decision-making and drug development support. Most of Klas’ experience comes from oncology drug development projects, but he has also touched on other therapeutic areas such as antibiotics, cardiovascular disease, and inflammatory diseases. He has analyzed data from a wide range of origins, from phase 0 to 4, PK, biomarkers, efficacy scales, safety endpoints, and adverse events.
Prior to joining qPharmetra Klas obtained a PhD in pharmacometrics at the University of Uppsala, Sweden, where he focused on models and methods for analysis of data from clinical trials involving D2-receptor antagonists.
In his spare time, if there is any, he likes to sail and sing.
Koen Jolling, PhD
Consultant
Koen joined qPharmetra in 2018, bringing extensive expertise in pharmacometrics, clinical pharmacology, and drug development. He holds an M.Sc. in Biology from the Catholic University of Leuven (2001) and a Ph.D. from Hasselt University (2008), where his research focused on the toxic effects of cadmium on renal function.
Koen’s career began at Johnson & Johnson as a data analyst in clinical pharmacokinetics and pharmacodynamics, contributing to drug development across multiple therapeutic areas. Post-Ph.D., he led PK and PK/PD efforts in in vitro, ADME, and toxicokinetic studies, supporting (pre)clinical programs in infectious diseases, gastrointestinal disorders, and virology. He also gained experience in strategic planning, CRO selection, and grant writing.
As head of pharmacokinetics and toxicokinetics at SGS Life Science Services for 2.5 years and later as a consultant at Exprimo for 5.5 years, Koen specialized in modeling and simulation to guide clinical pharmacology strategies.
At qPharmetra, Koen has honed his expertise in population PK modeling, exposure-response analysis, and model-based drug development, to optimize dosing and support clinical decisions.
Lars Lindbom, PhD
COO/CIO
Lars became a member of of qPharmetra in 2011. He completed his PhD in pharmacokinetics in 2006 at Uppsala University with Professors Mats Karlsson and Niclas Jonsson, and has been a consulting Pharmacometrician since 2007. He is the co-author of Perl-speaks-NONMEM (PsN), an enhanced toolkit for conducting population PK/PD modeling in NONMEM. Lars holds an MS in Molecular Biotechnology from Uppsala University and spent 1½ year as a Systems Developer before starting his PhD.
Lee Hodge, MBA
CFO
Lee was among the founding partners of qPharmetra in July 2010 as Chief Financial Officer, working from North Carolina. His current work focuses on the financial aspects of qPharmetra, with a focus on minimizing the administrative burden for the company, thus making it easier for clients to interact with qPharmetra. Prior to qPharmetra, Lee worked at Merck, GSK and Pharsight. He holds an MBA from Duke University. During his time at GSK, Pharsight and qPharmetra, he leveraged his finance and decision analysis training to inform drug development decisions.
Marita Prohn, MSc
Principal Consultant, Project and Resource Manager
Marita joined qPharmetra in August 2014. As a senior consultant, Marita has extensive experience in interpreting complex data, supporting clinical development teams in making the right decisions, optimizing dosing strategies, and informing regulatory submissions. In her current role, Marita works as an external consultant embedded in a client organization and is a project leader or analyst for stand-alone pharmacometric analyses. Marita likes variation in her daily work and works on projects across a wide range of therapeutic areas, such as cardiovascular and metabolic diseases, neuroscience, oncology, and infectious diseases. Her broad expertise, dedication, and leadership qualities in pharmacometrics make her a valuable contributor to advancing innovative drug therapies.
Her role also includes project and resource management, where she oversees project assignments and supports operational aspects of projects within qPharmetra.
Prior to joining qPharmetra, Marita worked for 8 years as an Associate Principal Scientist in Quantitative Pharmacology and Pharmacometrics at MSD in the Netherlands. In 2006, Marita obtained her MSc degree in Biomedical Engineering from Eindhoven University of Technology, where she completed a Master track in biomedical Imaging and Modeling.
Outside of work, Marita loves to play the flugelhorn in brass and marching bands. She lives with her family in a small town near ‘s Hertogenbosch in the Netherlands.
Max Lagraauw, PhD
Consultant
Max joined qPharmetra in October 2019, contributing to population PK and PKPD analyses to support dose selection, pediatric study designs, and regulatory labeling. He currently executes and reports population PK and PKPD modeling to regulatory standards, supports clinical development teams in decision-making, and contributes to regulatory submissions. Working across various therapeutic areas and drug development stages, Max provides critical analyses and insights that drive optimal dosing strategies and advance innovative therapies.
Max’s expertise includes population PK and PD modeling, non-compartmental analyses (qpNCA), probability of target attainment, model-based meta-analyses (MBMA), and clinical trial simulations. Beyond his technical work, Max is involved in business development, representing qPharmetra in client meetings, co-authoring Statements of Work, and contributing to marketing activities such as website and LinkedIn content.
Before qPharmetra, Max was a Project Pharmacometrician at Boehringer Ingelheim, supporting early oncology development. He earned his PhD in Biopharmaceutical Sciences in 2015, researching the innate immune system and cardiovascular disease, followed by a postdoctoral role applying modeling and simulation to amyotrophic lateral sclerosis drug development at Leiden Academic Centre for Drug Research.
Michelle Green, PhD
Principal Consultant, Team Lead Pharmacometrics
Michelle joined qPharmetra in 2021 with 14 years of experience as a Principal Pharmacometrics Consultant. She has quantitative drug development experience in oncology, hematology, cardiovascular disease, vaccines, and infectious diseases. Michelle’s enthusiasm for consulting is fueled by the opportunity to collaborate with clients across all phases of drug development, from population PK and PK/PD analyses in support of regulatory submissions to model-based meta-analyses informing go/no-go decisions.
Michelle takes a pragmatic approach to modeling and is appreciated by clients for her commitment to their success.
Nicolás Marco Ariño, PhD
Consultant
Nicolás joined qPharmetra in May 2022 as an Associate Consultant, working remotely from Valencia, Spain, and was promoted to Consultant in November 2024. His work encompasses all aspects of project delivery, with specialized skills in data management, PK/PD analysis, and first-in-human predictions. Prior to qPharmetra, Nicolás gained industry experience at AstraZeneca, contributing to various stages of drug development. He holds a master’s degree in clinical research from the Imperial Collage London and a PhD from the University of Navarra. His thesis focused on leveraging pharmacometrics to support decision-making in pain research and perioperative management.
Oskar Alskär, PhD
Senior Consultant
Oskar joined qPharmetra in May 2018 as an associate consultant, specializing in population PK and PKPD analyses to support regulatory submissions for drug approval in various disease areas such as oncology, ophthalmology, and inflammation. He obtained his PhD in Pharmaceutical Biosciences from the University of Uppsala in 2018. His thesis focused on mechanism-based models describing glucose homeostasis. During his Ph.D. he worked as a consultant at Pharmetheus applying his knowledge in various drug development projects.
Robin Michelet, PhD
Consultant, Team Lead PBPK
Robin joined qPharmetra in February 2022, contributing to projects in population PK/PD, PBPK, and minimal PBPK analyses. His work spans therapeutic areas and drug development stages, supporting clinical decisions from First-in-Human predictions to regulatory submissions. Robin uses advanced modeling tools to aid in decision-making across various study designs and special populations.
In addition to his technical expertise, which includes population PK/PD, PBPK, target attainment assessments, and clinical trial simulations, Robin leads the Berlin team and is involved in sales and marketing for qPharmetra.
Before joining, Robin was a Senior Scientist at Freie Universitaet Berlin, where he mentored 15 PhD students and continues part-time. He holds a BSc/MSc in Bio-science Engineering and a PhD in Pharmaceutical Sciences (2018) from Ghent University, specializing in pediatric drug research through IVIVE-PBPK, population PK/PD, and retrograde PBPK modeling.
Robin also has experience as a freelance consultant in pharmacometrics, working on antiviral biologics, bioequivalence studies, and PK/PD modeling of opioids.
In his free time, he spends time with his family traveling the world and collecting minerals (not rocks!) on the way.
Ségolène Siméon, PhD
Associate Consultant
Ségolène joined qPharmetra in February 2025 as an Associate Consultant. She is a pharmacist trained at the School of Pharmacy, Paris Descartes, with a specialization in pharmacometrics. Her initial interest in PBPK modeling led to a PhD from INERIS/AgroParisTech, where she used PBPK and multistate models to investigate the effects of valproic acid on zebrafish embryo development.
Ségolène further strengthened her expertise inclinical pharmacology and pharmacometrics during a 3-year post-doctorate fellowship at UCSF in collaboration withGenentech. There, she investigated the impact of malnutrition on lumefantrine exposure in young children using real-world data, assessed the pharmacokinetics and pharmacodynamics of linezolid, and developed a longitudinal disease model to characterize the treatment response in Crohn’s disease patients.
Following her postdoctoral work, Ségolène joined Differentia Bio, where she expanded her skill set in strategic planning, communication, and project management. She played a key role in fostering cross-team collaboration and contributed to the growth of the clinical pharmacology and pharmacometrics department.
At qPharmetra, Ségolène applies her expertise in population PKPD and PBPK modeling to support model-informed drug development strategies.
Tim Bergsma, PhD
Senior Consultant
Tim has consulted for the pharmaceutical industry since 2004 as a software developer, data manager, and modeler. He has worked in oncology, cardiology, neurology, immunology, virology, endocrinology, and infectious diseases, including PopPK and exposure-response work supporting drug approval by the FDA and EMA. He is expert at installation and configuration of NONMEM as well as transformation of its inputs and outputs. He has published more than a dozen R packages on CRAN and presents regularly at ACoP on pharmacometric methodology. His research interests include workflow optimization, systematic use of analysis metadata, and efficient visualization of results. Tim holds a doctorate in Ecology from Michigan State University, and held positions with Metrum Research Group (10 years) and Certara (5 years) before joining qPharmetra in 2019. He lives with his wife and family near Indianapolis.
Tomas Larsson, BSc
IT Manager
Tomas joined qPharmetra in January 2025 as IT Manager, with a focus on IT security and the modernization of IT systems. At qPharmetra, he leads initiative to strengthen cybersecurity and implement forward-looking technologies.
With over 20 years of experience in the IT field, Tomas has held positions such as IT Technician, IT Manager, and IT Development Manager, giving him a comprehensive undertanding of both operational and strategic IT needs.
Tomas holds a BSc in Computer Science and is dedicated to building secure, efficient, and future-ready IT infrastructure.
Undine Falkenhagen, PhD
Associate Consultant
Undine joined qPharmetra in March 2024 as an Associate Consultant, based in Berlin, Germany. At qPharmetra, she specializes in PBPK and nonlinear mixed effects models to support pharmacokinetic and pharmacodynamic decision-making. Prior to joining qPharmetra, she was pursuing her PhD in Applied Mathematics at the University of Potsdam as part of the PharMetrX graduate research program, which she has since completed magna cum laude.” Her research focused on model reduction in quantitative systems pharmacology, contributing to Bayesian precision dosing strategies, particularly in anticoagulant therapy. Holding an PhD in Mathematics, Undine brings experience in data analysis and mathematical modelling from her academic background, and she continues to apply these skills to innovative drug development projects.
Viktor Rognås, MSc
Data Scientist
Viktor joined qPharmetra in 2025 as a Data Scientist, where he contributes to the development of tools and workflows that accelerate pharmacometric modeling. He specializes in building reproducible pipelines, automating data preparation and reporting, and integrating software development with pharmacometric analysis.
Before joining qPharmetra, Viktor earned his MSc in Chemical Engineering and is currently pursuing a PhD in Pharmacometrics at Uppsala University. He brings experience from both industry (F. Hoffmann-La Roche) and regulatory work (Swedish Medical Products Agency), combining engineering rigor with pharmaceutical insight.